Hypolipidemic agents

Gemfibrozil is the generic name for an oral drug used to lower lipid levels.

Ezetimibe is a drug that lowers plasma cholesterol levels.

Niacin, also known as vitamin B3 and nicotinic acid, is an organic compound with the formula C6H5NO2 and, depending on the definition used, one of the 20 to 80 essential human nutrients.

Lomitapide (INN, marketed as Juxtapid in the US and as Lojuxta in the EU) is a drug used as a lipid-lowering agent for the treatment of familial hypercholesterolemia, developed by Aegerion Pharmaceuticals.

Lapaquistat (TAK-475) is a cholesterol-lowering drug.

Ezetimibe/atorvastatin (brand name Liptruzet) is a cholesterol lowering combination drug.

Acipimox (trade name Olbetam in Europe) is a niacin derivative used as a lipid-lowering agent.

Ezetimibe/simvastatin /ɛˈzɛtᵻmɪb ˌsɪmvəˈstætᵻn/ is a drug combination used for the treatment of dyslipidemia.

Evacetrapib was a drug under development by Eli Lilly & Company (investigational name LY2484595) that inhibits cholesterylester transfer protein (CETP), which transfers and thereby increases high-density lipoprotein and lowers low-density lipoprotein (CETP inhibitor]. It is thought that modifying lipoprotein levels modifies the risk of cardiovascular disease. The first CETP inhibitor, torcetrapib, was unsuccessful because it increased levels of the hormone aldosterone and increased blood pressure, which led to excess cardiac events when it was studied. Evacetrapib does not have the same effect. When studied in a small clinical trial in people with elevated LDL and low HDL, significant improvements were noted in their lipid profile.

Bococizumab (RN316) is a drug in development by Pfizer targeting PCSK9 to reduce LDL cholesterol.

Nicotinyl alcohol (pyridylcarbinol) is a niacin derivative used as a hypolipidemic agent and as a vasodilator.

Acetiromate is an antilipidemic drug which is used to treat hyperlipidemia.

Magnesium pyridoxal 5-phosphate glutamate (trade name Sedalipid) is a hypolipidemic agent.

Nafenopin is a hypolipidemic agent.

Niacin/lovastatin (trade names Advicor, Mevacor) is a drug combination used for the treatment of dyslipidemia.

Niacin/simvastatin (trade name Simcor, by Abbott) is a combination drug consisting of an extended release form of the vitamin niacin and the statin drug simvastatin.

Roxibolone (INN) (developmental code name BR-906), also known as 11β,17β-dihydroxy-17α-methyl-3-oxoandrosta-1,4-diene-2-carboxylic acid, is a steroidal antiglucocorticoid described as an anticholesterolemic (cholesterol-lowering) and anabolic drug which was never marketed.

Mipomersen (previously ISIS 301012, trade name Kynamro) is a cholesterol-reducing drug.

Benfluorex is an anorectic and hypolipidemic agent that is structurally related to fenfluramine patented and manufactured by a French pharmaceutical company Servier.

SCH-48461 is a cholesterol absorption inhibitor.

SCH 900271 is a nicotinic acid derivative designed to treat dyslipidemia.

Torcetrapib (CP-529,414, Pfizer) was a drug being developed to treat hypercholesterolemia (elevated cholesterol levels) and prevent cardiovascular disease.

Meglutol (INN, also known as 3-hydroxy-3-methylglutaric acid, β-hydroxy-β-methylglutaric acid, and dicrotalic acid) is a hypolipidemic agent.

Dextrothyroxine (trade name Choloxin) saw research as a cholesterol-lowering drug but was pulled due to cardiac side-effects.